



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/817,199	03/27/2001	Wei Shao	CL001187	9285

7590 05/11/2004  
CELERA GENOMICS CORPORATION  
45 West Gude Dr. C2#20  
Rockville, MD 20850

EXAMINER

RAWLINGS, STEPHEN L

ART UNIT PAPER NUMBER

1642

DATE MAILED: 05/11/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

**Application No.**

09/817,199

**Applicant(s)**

SHAO ET AL.

**Examiner**

Stephen L. Rawlings, Ph.D.

**Art Unit**

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 25 November 2003 and 23 February 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 4,8,9 and 24-31 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 25 and 29 is/are allowed.
- 6) ☒ Claim(s) 4, 8, 9, 24, 26--28, 30, and 31 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)             | 4) <input type="checkbox"/> Interview Summary (PTO-413)                             |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)    | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)         |
| Paper No(s)/Mail Date _____   | 6) <input checked="" type="checkbox"/> Other: <u>USPTO Search Report, pp. 1-2</u> . |

### **DETAILED ACTION**

1. The amendment filed November 25, 2003 is acknowledged and has been entered.
2. The supplemental amendment filed February 23, 2004 is acknowledged and has been entered. Claim 4 has been amended. Claims 30 and 31 have been added.
3. Claims 4, 8, 9, and 24-31 are pending in the application and are currently under prosecution.

#### ***Ground of Rejection Withdrawn***

4. The ground of rejection set forth in the previous Office action mailed August 25, 2003 has been withdrawn.

#### ***Claim Objections***

5. Claims 24 and 27 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claims 24 and 27 broaden the scope of the claims from which they depend. Presently claim 24, which depends from claim 9, recites, "a polypeptide comprising the amino acid sequence of SEQ ID NO:2"; and claim 9 is drawn to a host cell containing the vector of claim 8. Claim 27, which depends from claim 8, recites, "a polypeptide comprising SEQ ID NO:2". Claim 8 is drawn to a vector comprising the nucleic acid molecule of claim 4. Claim 4, however, is limited to a nucleic acid molecule consisting of a nucleotide sequence encoding a polypeptide consisting of SEQ ID NO: 2, SEQ ID NO: 1, SEQ ID NO: 3, or the full complement of a nucleic acid molecule consisting of a nucleotide sequence encoding a polypeptide consisting of SEQ ID NO: 2, SEQ ID NO: 1, or SEQ ID NO: 3; accordingly, the nucleic acid molecule of claim 4 can only encode a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2. Appropriate correction is required.

***Claim Rejections - 35 USC § 102***

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

7. Claims 4, 8, 9, 24, 26-28, 30, and 31 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent No. 6,569,662 B1, as evidenced by the attached USPTO Search Report “us-09-817-199c-2.rge”, Result No. 1.

As evidenced by the USPTO Search Report “us-09-817-199c-2.rge” (Result No. 1), US Patent No. 6,569,662 B1 (‘662) teaches the polynucleotide sequence of an isolated nucleic acid molecule encoding a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 2, a vector comprising said polynucleotide sequence, a host cell comprising said vector, and a method for producing said polypeptide comprising culturing said host cell under conditions appropriate to produce the polypeptide and recovering the polypeptide; see, e.g., SEQ ID NO: 959 of the sequence listing; columns 171 and 172, Table 2; and column 3, lines 49-58. ‘662 teaches the vector can be a viral vector or a plasmid or phage; see, e.g., column 9, line 54, through column 10, line 18. ‘662 teaches the vector can comprise an operatively linked promoter; see, e.g., column 9, line 54, through column 10, line 18. ‘62 teaches the polynucleotide sequence can be joined to heterologous polynucleotide sequence encoding a heterologous amino acid sequence; see, e.g., column 15, lines 3-10; and column 14, lines 49-53.

***Conclusion***

8. Claims 4, 8, 9, 24, and 26-31 are rejected. Claims 25 and 29 are allowable.

Art Unit: 1642


9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephen L. Rawlings, Ph.D. whose telephone number is (571) 272-0836. The examiner can normally be reached on Monday-Friday, 8:30AM-5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne (Bonnie) Eyler, Ph.D. can be reached on (571) 272-0871. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Stephen L. Rawlings, Ph.D.  
Examiner  
Art Unit 1642

slr  
April 21, 2004

  
YVONNE EYLER, PH.D.  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - nucleic search, using frame\_plus\_p2n model

Run on: March 19, 2004, 18:08:08 ; Search time 3729 Seconds  
(without alignments)  
2591.981 Million cell updates/sec

Title: US-09-817-199C-2  
Perfect score: 1150  
Sequence: 1 MTGPGAVATRDGEAPERSP.....FGIRDYVESQKRRSCCSFM 223

Scoring table:  
BLOSUM62  
Xgapop 10.0 , Xgapext 0.5  
Ygapop 10.0 , Ygapext 0.5  
Fgapop 6.0 , Fgapext 7.0  
Delop 6.0 , Delext 7.0

Searched: 3470272 seqs, 21671516995 residues  
Total number of hits satisfying chosen parameters: 6940544

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Command line parameters:  
-MODE=frame\_plus\_p2n.model -DEV=x1h  
-O=/cgn2.1/USPTO.spool/US09817199/runat.15032004.144838.22060/app.query.fasta\_1.391  
-DB=GenEmbl -QFWT=fastap -SUFFIX=rge -MINMATCH=0.1 -LOOFC=0 -LOOEXT=0  
-UNITS=bits -START=1 -END=1 -MATRIX=blosum62 -TRANS=human40.cdi -LIST=45  
-DOCLIGN=200 -THR.SCOR=PCT -THR.MAX=100 -THR.MIN=0 -ALIGN=15 -MODE=LOCAL  
-OUTFMT=Plc -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000  
-USER=US09817199@cgn2.1.1.371.runat.15032004.144838.22060 -NCPU=6 -ICPU=3  
-NO MAP -LARGEDUTERY -NEG.SCOR=0 -WAIT -DSPLOCK=100 -LONGLOG  
-DEV TIMEOUT=120 -MARN TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOP=6  
-FGAPEXT=7 -YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : GenEmbl:\*

1:	gb_ba:*
2:	gb_hg:*
3:	gb_in:*
4:	gb_cm:*
5:	gb_ov:*
6:	gb_pat:*
7:	gb_ph:*
8:	gb_pl:*
9:	gb_pr:*
10:	gb_ro:*
11:	gb_stb:*
12:	gb_sy:*
13:	gb_un:*
14:	gb_vt:*
15:	em_da:*
16:	em_fun:*
17:	em_hum:*
18:	em_in:*
19:	em_mu:*
20:	em_cm:*
21:	em_or:*
22:	em_ov:*
23:	em_pat:*
24:	em_ph:*
25:	em_pl:*
26:	em_ro:*
27:	em_stb:*
28:	em_un:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
29:	em_vi:*				
30:	em_hg_hum:*				
31:	em_hg_inv:*				
32:	em_hg_other:*				
33:	em_hg_mus:*				
34:	em_hg_pin:*				
35:	em_hg_rod:*				
36:	em_hg_mam:*				
37:	em_hg_vrt:*				
38:	em_sy:*				
39:	em_hg_hum:*				
40:	em_hg_mus:*				
41:	em_hg_other:*				
1	1150	100.0	1106	6 AR339468	AR339468 Sequence
2	1150	100.0	1700	9 BC016615	BC016615 Homo sapi
3	1150	100.0	1977	6 AX835179	AX835179 Sequence
4	1150	100.0	1977	9 AK098068	AK098068 Homo sapi
5	1150	100.0	2612	6 AR220901	AR220901 Sequence
6	1145	99.6	1116	6 AX236082	AX236082 Sequence
7	1081	94.0	690	10 AF233582	AF233582 Mus muscu
8	1081	94.0	2216	10 BC050757	BC050757 Mus muscu
9	1004	87.3	842	6 AR403539	AR403539 Sequence
10	1004	87.3	842	6 BD137355	BD137355 Opening s
11	977	85.0	576	6 AX236084	AX236084 Sequence
12	969	84.3	576	6 BD103204	BD103204 Factors i
13	942	81.9	576	6 BD103203	BD103203 Factors i
14	913	79.4	1745	6 BC040547	BC040547 Homo sapi
15	842.5	73.3	3804	9 AK127073	AK127073 Homo sapi
16	787	68.4	771	6 AX823550	AX823550 Sequence
17	787	68.4	968	6 AX823552	AX823552 Sequence
18	784.5	68.2	1404	10 BC061984	BC061984 Rattus no
19	780.5	67.9	1504	9 BC007681	BC007681 Homo sapi
20	757	65.8	1320	9 AB027137	AB027137 Homo sapi
21	754	65.6	1098	10 RNT18771	U18771 Rattus norv
22	753	65.5	573	9 AF498952	AF498952 Homo sapi
23	731	63.6	1340	6 AR062279	AR062279 Sequence
24	710.5	61.8	3105	6 AX713444	AX713444 Sequence
25	710.5	61.8	3105	9 AK054846	AK054846 Homo sapi
26	649.5	56.5	2536	3 AY061826	AY061826 Drosophila
27	585.5	45.7	1002	8 AK111912	AK111912 Oryza sat
28	525.5	45.7	1022	8 AK112029	AK112029 Oryza sat
29	521.5	45.3	1337	10 BC019990	BC019990 Mus muscu
30	518.5	45.1	1074	8 AB024994	AB024994 Cicer ari
31	517.5	45.0	2145	3 DD18453	M34456 Dictyostell
32	517.5	45.0	151802	3 AC114263	AC114263 Dictyoste
33	516	44.9	638	10 S53270	S53270 MEL-BAS-rel
34	516	44.9	765	5 DY00RA2	M38391 Discopryge o
35	516	44.9	911	8 AY084345	AY084345 Arabidops
36	516	44.9	2048	9 BC002977	BC002977 Homo sapi
37	516	44.9	2818	9 AK025165	AK025165 Homo sapi
38	514.5	44.7	4749	10 BC059208	BC059208 Mus muscu
39	513.5	44.7	624	9 AF498943	AF498943 Homo sapi
40	513.5	44.7	624	9 BT007184	BT007184 Homo sapi
41	513.5	44.7	624	12 BT008275	BT008275 Synthetic
42	513.5	44.7	660	9 HSMRAB8	X56741 H.sapiens m
43	513.5	44.7	740	10 RNU53475	US3475 Rattus norv
44	513.5	44.7	760	10 CFRAB8	X56385 Canine rab8
45	513.5	44.7	782	8 PEA0TBP09	D12548 Pisum sativ

RESULT 1

## ALIGNMENTS

AR339468  
 LOCUS AR339468 1106 bp DNA linear PAT 17-AUG-2003  
 DEFINITION Sequence 959 from patent US 6569662.  
 ACCESSION AR339468  
 VERSION AR339468.1 GI:33726325  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 1106)  
 AUTHORS Tang, Y.T., Zhou, P. and Dmanac, R.T.  
 TITLE Nucleic acids and polypeptides  
 JOURNAL Patent: US 6569662-A 959 27-MAY-2003;  
 FEATURES  
 source 1..1106  
 /organism="Unknown"  
 /mol\_type="genomic DNA"

ORIGIN  
 Alignment Scores:  
 Pred. No.: 1376-108 Length: 1106  
 Score: 1150.00 Matches: 223  
 Percent Similarity: 100.00% Conservative: 0  
 Best Local Similarity: 100.00% Mismatches: 0  
 Query Match: 100.00% Indels: 0  
 Gaps: 0

US-09-817-199C-2 (1-223) x AR339468 (1-1106)

QY 1 MetThrGlyThrProGlyValAlaValAlaThrArgAspGlyGluAlaProGluArgSerPro 20  
 DB 28 ATGACGGGCAAGCCGAGGCGCCCTTCCACCGGAGTGGCGAGGCCCGGAGCGCTCCCG 87  
 QY 21 ProCysSerProSerTyrAspLeuThrGlyValMetLeuLeuGlyAspThrGlyVal 40  
 DB 88 CCTGCACTCGAGCTGACCTGACCTGCGGAGGAGTGTCTTGGGAGACACAGGCGTC 147  
 QY 41 GlyLysThrCysPheLeuLeuGlnPheLysAspGlyValPheLeuSerGlyThrPheLe 60  
 DB 148 GGCAGAAACATGTTCTCTATCCAAATTCAGAGCGGCGCTTCTCGGAACTTCATTA 207  
 QY 61 AlaThrValGlyIleAspPheArgAsnLysValIleThrValAspGlyValArgValLys 80  
 DB 208 GGCACCGCTCGGATGACTTCAGGAAACAGGTGTGATGCTGATGGCTGAGTGAAG 267  
 QY 81 LeuGlnIleTyrAspThrAlaGlyGlnGluArgPheArgSerValThrHisAlaTyrTyr 100  
 DB 268 CTGCAGATCTGGGACACCGCTGGGAGGACGTTCCGAGAGTCAACCATGCTTATTAC 327  
 QY 101 ArgAspAlaGlnAlaLeuLeuLeuLeuTyrAspIleThrAsnLysSerSerPheAspAsn 120  
 DB 328 AGAGATGCTCAGGCGCTTCTCTGCTGATGACATCAACCAATCTTCTTGCACAC 387  
 QY 121 IleArgAlaTyrPheLeuThrGlnIleHisGluTyrAlaGlnArgAspValIleMetLeu 140  
 DB 388 ATCAGAGCGCTGCTCAGTCACTGATCATAGATGCCAGAGGAGTGTATCATGTG 447  
 QY 141 LeuGlyAsnLysAlaAspMetSerSerGluArgValIleArgSerGlyAspGlyThr 160  
 DB 448 CTAGGCAACAGAGCGGATGAGCAGCAAGAGATGATCCGTCGAGAGAGGAGAGACC 507  
 QY 161 LeuAlaArgGluTyrGlyValProPheLeuGluThrSerAlaLysThrGlyMetAsnVal 180  
 DB 508 TTGGCCAGGAGATGAGGTTCCTTCTGAGAGCAGCGCAAGACTGGCATGATGTG 567  
 QY 181 GluLeuAlaPheLeuAlaIleAlaLysGluLeuLysTyrArgAlaGlyHisGlnAlaAsp 200  
 DB 568 GAGTTAGCTTCTTCTGCGCATCGCCAGAGAACTGAAATACCGGCGCGGATCAAGCGGAT 627  
 QY 201 GluProSerPheGlnIleArgAspTyrValGluSerGluLysArgSerSerCysGly 220  
 DB 628 GAGCCCAAGCTTCAGATCGAGATGATGTAGATGCCAGAGAGCGCTCCAGCTGCTGC 687

QY 221 SerPheMet 223  
 DB 688 TCCTTCATG 696

RESULT 2  
 BC016615  
 LOCUS  
 DEFINITION  
 ACCESSION  
 VERSION  
 KEYWORDS  
 SOURCE  
 ORGANISM

REFERENCE  
 AUTHORS

BC016615 1700 bp mRNA linear PRI 04-OCT-2003  
 Homo sapiens RAB37, member of RAS oncogene family, mRNA (cDNA clone MGC:21391 IMAGE:4520191), complete cds.  
 BC016615  
 EC016615.1 GI:16741620  
 MGC.  
 Homo sapiens (human)  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 1 (bases 1 to 1700)  
 Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G., Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D., Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K., Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F., Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L., Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L., Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S., Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J., Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J., McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richardson, S., Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hult, S.W., Villalon, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A., Fahey, J., Helton, E., Kettman, M., Madan, A., Rodriguez, S., Sanchez, A., Whitting, M., Madan, A., Young, A.C., Shevchenko, Y., Bouffard, G.G., Blakeley, R.W., Touchman, J.W., Green, E.D., Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M., Butlerfield, Y.S., Krzywinski, M.I., Skalska, J., Smalins, D.E., Schnerch, A., Schein, J.E., Jones, S.J., and Marra, M.A.  
 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences  
 Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)  
 22386257  
 12477932  
 2 (bases 1 to 1700)  
 Strausberg, R.  
 Direct Submission  
 Submitted (31-OCT-2001) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA  
 NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
 Contact: MGC help desk  
 Email: [cgabbs-remail.nih.gov](mailto:cgabbs-remail.nih.gov)  
 Tissue Procurement: DCTD/DTF  
 cDNA Library Preparation: Life Technologies, Inc.  
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)  
 DNA Sequencing by: Baylor College of Medicine Human Genome Sequencing Center  
 Center code: BCM-HGSC  
 Web site: <http://www.hgsc.bcm.tmc.edu/cdna/>  
 Contact: [amg@bcm.tmc.edu](mailto:amg@bcm.tmc.edu)  
 Gunaratne, P.H., Garcia, A.M., Lu, X., Hult, S.W., Louised, H., Kowib, C.R., Sneed, A.J., Martin, R.G., Muzny, D.M., Nambatti, A.N., Gibbs, R.A.  
 Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at: <http://image.llnl.gov>  
 Series: IRK Plate: 28 Row: J Column: 15.  
 Location/Qualifiers  
 1..1700  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /clone="MGC:21391 IMAGE:4520191"  
 /issue\_type="Prostate, adenocarcinoma."  
 /clone\_id="NIH\_MGC\_91"